The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight
The journal of pharmacology and experimental therapeutics/The Journal of pharmacology and experimental therapeutics